Valeritas (NASDAQ: VLRX) is one of 106 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Valeritas to similar companies based on the strength of its profitability, dividends, valuation, analyst recommendations, institutional ownership, earnings and risk.
Get Valeritas alerts:
This table compares Valeritas and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Valeritas and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Valeritas||$20.25 million||-$49.30 million||-0.18|
|Valeritas Competitors||$1.51 billion||$110.16 million||-207.43|
Valeritas’ rivals have higher revenue and earnings than Valeritas. Valeritas is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Valeritas has a beta of 4.45, indicating that its share price is 345% more volatile than the S&P 500. Comparatively, Valeritas’ rivals have a beta of 0.77, indicating that their average share price is 23% less volatile than the S&P 500.
Insider & Institutional Ownership
4.9% of Valeritas shares are held by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 1.2% of Valeritas shares are held by company insiders. Comparatively, 16.0% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for Valeritas and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valeritas presently has a consensus price target of $12.00, indicating a potential upside of 705.37%. As a group, “Surgical & medical instruments” companies have a potential upside of 2.50%. Given Valeritas’ higher probable upside, equities analysts clearly believe Valeritas is more favorable than its rivals.
Valeritas rivals beat Valeritas on 10 of the 13 factors compared.
Valeritas, Inc. is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin. Its development portfolio also includes the h-Patch technology, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans microneedle transdermal delivery patch. Its h-Patch is a controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. The Mini-Ject represents needle-free injection system, combining a range of fully disposable pre-filled options. Micro-Trans microneedle array patch technology enables drug delivery into the dermis without limitations of drug size, structure, charge or the patient’s skin characteristics.